Teladoc Health filings document the company’s virtual care operations, financial reporting, governance structure, equity compensation practices, and common-stock matters. Recent Form 8-K reports furnish quarterly and annual results releases, including segment disclosures for Integrated Care and BetterHelp, adjusted EBITDA measures, outlook commentary, and cash-flow information.
The company’s proxy and current reports also disclose board composition, director appointments and retirements, audit, compensation, and nominating and corporate governance committee assignments, director independence determinations, and non-employee director compensation arrangements. Other filings cover amendments to the 2023 Employment Inducement Incentive Award Plan, shares reserved for issuance, inducement awards, Regulation FD exhibits, and related governance disclosures under NYSE and SEC rules.
Form 144 filing for Teladoc Health, Inc. (TDOC) shows proposed sale of 4,149 common shares through Fidelity Brokerage Services with an aggregate market value of $31,490.91, to be sold on or about 09/03/2025 on the NYSE. The filer reports acquiring these shares by restricted stock vesting on 09/01/2025, recorded as compensation. The issuer's outstanding shares are listed as 176,690,662.
The filing also discloses sales by the same person in the past three months: 4,174 shares sold 06/03/2025 for $28,842.34 and 2,383 shares sold 09/02/2025 for $18,075.77. The signer certifies no undisclosed material adverse information.
Teladoc Health, Inc. (TDOC) Form 144 shows an insider intends to sell 2,383 common shares acquired by restricted stock vesting and held for compensation. The shares are scheduled for sale through Fidelity Brokerage Services on the NYSE with an aggregate market value of $18,075.77 based on the filing. The filer reports prior small open-market sales during June totaling 6,532 shares for gross proceeds of $45,018.22. The securities were acquired and the vesting/compensation payment occurred on the same date indicated in the filing. The filing includes the signer’s representation that they are not aware of any undisclosed material adverse information about the issuer.
Teladoc Health, Inc. (TDOC) Form 144 summary: This notice reports a proposed sale of 4,700 common shares through Fidelity Brokerage Services with an aggregate market value of $35,650.91, to be executed approximately on 09/02/2025 on the NYSE. The shares were acquired on 08/29/2025 as restricted stock vesting and were paid as compensation. The filing also discloses a prior sale by the same account: 4,653 shares sold on 06/02/2025 for $31,919.58. The filing includes the total number of shares outstanding reported as 176,690,662 and contains the required certification that the seller is not aware of undisclosed material adverse information.
Form 144 filed for Teladoc Health, Inc. (TDOC) by a selling person reporting a proposed sale of 3,998 shares of common stock through Fidelity Brokerage Services on the NYSE with an aggregate market value of $30,326.03. The filer states the shares were acquired on 08/29/2025 via restricted stock vesting as compensation and that payment was completed on that date. The notice lists one sale in the prior three months: 3,958 shares sold on 06/02/2025 for $27,151.88. The signer certifies no undisclosed material adverse information.
Teladoc Health, Inc. (TDOC) Form 144 shows an insider sale notice for 5,867 common shares, with an aggregate market value of $44,502.95, reported for an approximate sale date of 09/02/2025 on the NYSE. The shares were acquired by restricted stock vesting on 08/29/2025 and are being sold as compensation. The filer also reported a prior sale of 5,808 shares on 06/02/2025 for gross proceeds of $39,842.88. Outstanding shares are listed as 176,690,662, indicating the disclosed transactions represent a very small fraction of total shares.
Form 144 notice for Teladoc Health, Inc. (TDOC) shows a proposed sale of 12,846 common shares with an aggregate market value of $97,440.77 and an approximate sale date of 09/02/2025 on the NYSE. The filing reports the shares were acquired on 08/29/2025 through restricted stock vesting from the issuer and the payment nature is listed as compensation, indicating these are insider-awarded shares becoming eligible for sale.
The filing also discloses a sale by Mala Murthy of 13,856 shares on 06/02/2025 with gross proceeds of $95,052.16. The notice includes the filer’s representation that they are not aware of undisclosed material adverse information about the issuer. Shares outstanding are reported as 176,690,662.
TDOC Q2 2025 10-Q highlights:
- Revenue slipped 1.6 % YoY to $631.9 m; six-month revenue down 2.1 % to $1.26 bn. U.S. contributed 82 % of sales.
- Losses narrowed sharply. Q2 net loss was $32.7 m (-$0.19/sh) versus -$837.7 m (-$4.92/sh) a year ago, mainly because 2024 contained a $790 m goodwill charge. YTD loss is -$125.7 m (-$0.72/sh) versus -$919.6 m.
- Operating efficiency improved: EBITDA ex-items rose to $69.3 m vs. $89.5 m LY but YTD cash from ops increased to $107.4 m (+10 %). Advertising & marketing trimmed 1.6 %.
- Balance-sheet shifts: Cash fell to $679.6 m from $1.30 bn after $550.6 m retirement of 2025 convertible notes. Only $1 bn 1.25 % 2027 notes remain outstanding. Equity slipped 4.6 % to $1.42 bn; debt-to-equity now 0.70x.
- Intangibles & goodwill: New $59.1 m goodwill from Catapult Health was fully impaired, bringing total YTD impairment to the same amount versus $790 m LY. Intangibles amortization was $88.7 m for the quarter.
- Segment view: Integrated Care revenue +3.7 % YoY while BetterHelp -9.3 %. Integrated Care generated $57.5 m Adjusted EBITDA; BetterHelp $11.9 m.
- Liquidity backstop: On 17 Jul 2025 company executed a new five-year $300 m secured revolving credit facility with variable SOFR+2.75–3.25 % pricing.
Key takeaways: Profitability metrics and cash generation improved despite modest top-line softness, but cash reserves contracted materially after note redemptions and goodwill impairments continue to weigh on equity.